Literature DB >> 16885659

Ovarian remnant syndrome.

Paul M Magtibay1, Javier F Magrina.   

Abstract

Ovarian remnant syndrome (ORS) refers to a condition occurring in women who have had a bilateral salpingo-oophorectomy (BSO), with or without a hysterectomy, that leaves behind ovarian tissue. This residual ovarian tissue then results in pelvic pain or a pelvic mass. Risk factors associated with incomplete removal of an ovary and subsequent development of ORS include a history of endometriosis, pelvic inflammatory disease, multiple previous surgeries, and pelvic adhesive disease. Patients most frequently present with chronic pelvic pain, pelvic pain associated with a pelvic mass, or an asymptomatic pelvic mass. Definitive criteria for diagnosis of ORS include a history of BSO with histologic documentation of ovarian tissue obtained during subsequent surgical excision. The recommended treatment for ORS is surgical excision by laparotomy or, more recently, laparoscopy. We present the presentation and management of patients with ORS and a review of the published literature.

Entities:  

Mesh:

Year:  2006        PMID: 16885659     DOI: 10.1097/00003081-200609000-00012

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  3 in total

1.  Ovarian remnant syndrome at the trochar site: a report of a rare complication following laparoscopic ovarian surgery.

Authors:  Ki Yong Na; Ji-Youn Sung; Kyu Yeoun Won; Gou Young Kim; Sung-Jig Lim; Suk-Hwan Lee
Journal:  Korean J Pathol       Date:  2013-06-25

2.  Malignant neoplasia arising from ovarian remnants following bilateral salpingo-oophorectomy (Review).

Authors:  Atsushi Imai; Kazutoshi Matsunami; Hiroshi Takagi; Satoshi Ichigo
Journal:  Oncol Lett       Date:  2014-04-25       Impact factor: 2.967

3.  Late aortic lymphocele and residual ovary syndrome after gynecological surgery.

Authors:  Maria Pastore; Natalina Manci; Claudia Marchetti; Francesca Esposito; Marialetizia Iuliano; Lucia Manganaro; Pierluigi Benedetti Panici
Journal:  World J Surg Oncol       Date:  2007-12-28       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.